Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Autoimmune Disorders01:29

Autoimmune Disorders

Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune system...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Automated cassette-based synthesis, metabolism, and dosimetry of [<sup>18</sup>F]ApaScan, a PET tracer for aldosterone synthase imaging.

Nuclear medicine and biology·2026
Same author

Partial pressure of oxygen-guided adrenal venous sampling in primary aldosteronism.

The Journal of clinical endocrinology and metabolism·2026
Same author

PyCaret machine learning library with three preprocessing steps after eLORETA source estimation predicts Alzheimer's disease.

Neuroimage. Reports·2026
Same author

A case of adrenal endothelial cyst (vascular type) with positive <sup>123</sup>I-MIBG uptake.

Urology case reports·2025
Same author

Artificial intelligence identifies individuals with prediabetes using single-lead electrocardiograms.

Cardiovascular diabetology·2025
Same author

Gait and frontal lobe function become associated in patients with idiopathic normal pressure hydrocephalus after shunt surgery.

Frontiers in neurology·2025

Related Experiment Video

Updated: May 9, 2026

A Simple Cell-based Immunofluorescence Assay to Detect Autoantibody Against the N-Methyl-D-Aspartate (NMDA) Receptor in Blood
07:20

A Simple Cell-based Immunofluorescence Assay to Detect Autoantibody Against the N-Methyl-D-Aspartate (NMDA) Receptor in Blood

Published on: January 9, 2018

Cognitive dysfunction associated with anti-glutamic acid decarboxylase autoimmunity: a case-control study.

Masahito Takagi1, Yasushi Ishigaki, Kenji Uno

  • 1Department of Behavioral Neurology and Cognitive Neuroscience, Tohoku University Graduate School of Medicine, Sendai, Japan. mastakagi@med.tohoku.ac.jp

BMC Neurology
|July 10, 2013
PubMed
Summary

Patients with anti-glutamic acid decarboxylase antibodies (GADA) and diabetes show increased cognitive decline. This suggests GADA may contribute to cognitive impairment independently of other neurological issues in diabetic patients.

More Related Videos

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis
05:55

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis

Published on: December 1, 2023

Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis
26:48

Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis

Published on: July 4, 2007

Related Experiment Videos

Last Updated: May 9, 2026

A Simple Cell-based Immunofluorescence Assay to Detect Autoantibody Against the N-Methyl-D-Aspartate (NMDA) Receptor in Blood
07:20

A Simple Cell-based Immunofluorescence Assay to Detect Autoantibody Against the N-Methyl-D-Aspartate (NMDA) Receptor in Blood

Published on: January 9, 2018

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis
05:55

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis

Published on: December 1, 2023

Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis
26:48

Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis

Published on: July 4, 2007

Area of Science:

  • Neuroscience
  • Immunology
  • Endocrinology

Background:

  • Glutamic acid decarboxylase (GAD) synthesizes GABA, a key neurotransmitter.
  • Anti-GAD antibodies (GADA) are linked to neurological disorders and type 1 diabetes.
  • The non-motor symptoms and dementia risk in GADA-positive diabetes are not well understood.

Purpose of the Study:

  • To investigate cognitive function in patients with GADA-positive diabetes.
  • To compare cognitive performance against GADA-negative type 2 diabetes patients.

Main Methods:

  • Included 21 GADA-positive diabetic patients and 19 GADA-negative type 2 diabetes controls.
  • Subjects underwent comprehensive neuropsychological testing.
  • Brain MRI was performed to assess neurological changes.

Main Results:

  • GADA-positive patients exhibited significantly lower neuropsychological test scores.
  • 57% of GADA-positive subjects had impaired cognitive performance versus 21% in controls (p=0.027).
  • No significant differences in demographics, diabetic severity, or brain MRI findings were observed.

Conclusions:

  • GADA-positive diabetic patients face a higher risk of cognitive decline.
  • GADA may be independently associated with cognitive decline in diabetes.
  • Further research is needed to understand the mechanisms linking GADA, diabetes, and cognitive impairment.